All Bell ceremonies

Isabelle Kocher from GDF SUEZ opens the European trading day in Paris

GDF SUEZ celebrates success of largest Green Bond issues with major investors  and partners during ring bell ceremony hosted by Euronext in Paris

Isabelle Kocher from GDF SUEZ opens the European trading day in Paris

GDF SUEZ celebrates success of largest Green Bond issues with major investors  and partners during ring bell ceremony hosted by Euronext in Paris

EnterNext welcomes Innoveox on Alternext in Paris

Innoveox specializes in environmental services. The group provides a technology of hydrothermal oxidation in supercritical environment to industries and communities for the processing of any form of hazardous industrial waste (oil, solvents, pesticides, etc.) and complex, corrosive and resistant waste. The technology consists in putting the effluent to be treated under pressure and temperature, and injecting the oxygen immediately soluble and causing oxidation and almost complete destruction of the organic matter. The water from the process can be discharged directly in the environment or recycled, whereas the metals and minerals can be precipitated and recycled.

EnterNext welcomes Innoveox on Alternext in Paris

Innoveox specializes in environmental services. The group provides a technology of hydrothermal oxidation in supercritical environment to industries and communities for the processing of any form of hazardous industrial waste (oil, solvents, pesticides, etc.) and complex, corrosive and resistant waste. The technology consists in putting the effluent to be treated under pressure and temperature, and injecting the oxygen immediately soluble and causing oxidation and almost complete destruction of the organic matter. The water from the process can be discharged directly in the environment or recycled, whereas the metals and minerals can be precipitated and recycled.

Young student entrepreneurs from various schools in the Ile de France region

The students were invited by Euronext for an intensive training session in order to prepare the Regional Championship taking place in June 2014 prcede by ringing the opening bell . This falls under the initiative of the Corporate Responsibility Group at Euronext. 

Young student entrepreneurs from various schools in the Ile de France region

The students were invited by Euronext for an intensive training session in order to prepare the Regional Championship taking place in June 2014 prcede by ringing the opening bell . This falls under the initiative of the Corporate Responsibility Group at Euronext. 

Mr. Peter Crosby, President and CEO of Mainstay Medical, opens the European trading day in Paris

Mainstay Medical is an Irish medical device company that is developing an innovative implantable neurostimulation device, ReActiv8, for people with debilitating Chronic Low Back Pain.

Chronic Low Back Pain is generally defined as Low Back Pain where the pain persists for more than three months. Low Back Pain is a leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments. The Company estimates that in approximately 7% of all cases of Low Back Pain, the pain persists for more than three months.

ReActiv8 represents a new approach to the treatment of Chronic Low Back Pain. ReActiv8 is an implantable neurostimulation device which applies electrical stimulation to nerves that supply one of the key stabilising muscles in the back, the lumbar multifidus muscle. The hypothesis on which ReActiv8 is based is that electrical stimulation of the nerve that innervates the lumbar multifidus muscle to cause contraction of the muscle can help reactivate the muscle control system, thereby leading to improved spine stability and a reduction in the effects of CLBP.

Further information is available at www.mainstay-medical.com

Mr. Peter Crosby, President and CEO of Mainstay Medical, opens the European trading day in Paris

Mainstay Medical is an Irish medical device company that is developing an innovative implantable neurostimulation device, ReActiv8, for people with debilitating Chronic Low Back Pain.

Chronic Low Back Pain is generally defined as Low Back Pain where the pain persists for more than three months. Low Back Pain is a leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments. The Company estimates that in approximately 7% of all cases of Low Back Pain, the pain persists for more than three months.

ReActiv8 represents a new approach to the treatment of Chronic Low Back Pain. ReActiv8 is an implantable neurostimulation device which applies electrical stimulation to nerves that supply one of the key stabilising muscles in the back, the lumbar multifidus muscle. The hypothesis on which ReActiv8 is based is that electrical stimulation of the nerve that innervates the lumbar multifidus muscle to cause contraction of the muscle can help reactivate the muscle control system, thereby leading to improved spine stability and a reduction in the effects of CLBP.

Further information is available at www.mainstay-medical.com

Make-A-Wish France, Maison Lenôtre and wish child Victor celebrate World Wish Day in Paris

Euronext supports Make-A-Wish France who grants wishes for children with life-threatening medical conditions. For the 5th edition of World Wish Day, Make-A-Wish France is invited to celebrate the anniversary of the first wish granted. A ceremony will take place where Victor,  Wish Child of the day, will be put in the spotlight. Victor's wish  was granted in April with the support of Maison Lenôtre: "I wish to make pastry with a famous Chef".

Make-A-Wish France, Maison Lenôtre and wish child Victor celebrate World Wish Day in Paris

Euronext supports Make-A-Wish France who grants wishes for children with life-threatening medical conditions. For the 5th edition of World Wish Day, Make-A-Wish France is invited to celebrate the anniversary of the first wish granted. A ceremony will take place where Victor,  Wish Child of the day, will be put in the spotlight. Victor's wish  was granted in April with the support of Maison Lenôtre: "I wish to make pastry with a famous Chef".

EnterNext welcomes Theraclion on Alternext in Paris

Theraclion specializes in developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.

EnterNext welcomes Theraclion on Alternext in Paris

Theraclion specializes in developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.

The Manitou Group celebrates the 30th anniversary of its IPO

The Manitou group has a genuine right to acknowledge itself as a midsize company : As a French industrial group with 3,200 employees, of which, more than half in France, 75% of Manitou’s sales were realized internationally in 2013. Since its founding, the group designs, assembles and distributes material handling solutions, equipment, throughout the entire world for the construction, agricultural and industrial markets. Wherever it’s necessary to lift, load, place or store, you’ll find Manitou forklifts, telehandlers or aerial work platforms. The Manitou group depends on the quality, innovation and reliability of its products as well as its expertise and know-how.

The Manitou Group celebrates the 30th anniversary of its IPO

The Manitou group has a genuine right to acknowledge itself as a midsize company : As a French industrial group with 3,200 employees, of which, more than half in France, 75% of Manitou’s sales were realized internationally in 2013. Since its founding, the group designs, assembles and distributes material handling solutions, equipment, throughout the entire world for the construction, agricultural and industrial markets. Wherever it’s necessary to lift, load, place or store, you’ll find Manitou forklifts, telehandlers or aerial work platforms. The Manitou group depends on the quality, innovation and reliability of its products as well as its expertise and know-how.

EnterNext welcomes AwoX on Euronext's market in Paris

Alain Molinié, CEO of AwoX, opens the European trading day in Paris.

AwoX specializes in designing and developing applications and connection technologies to audio and video (primarily TV-sets, tablets and smartphones) based on the Digital Living Network Alliance (DLNA) in order to share multimedia contents between those devices.
The company’s software development kits allows modernizing a stereo system for music listening from a computer, transforming a TV-set into a tool for watching videos from smartphone or the Web, and also converting a standard bulb into a loud speaker connected to a tablet.

EnterNext welcomes AwoX on Euronext's market in Paris

Alain Molinié, CEO of AwoX, opens the European trading day in Paris.

AwoX specializes in designing and developing applications and connection technologies to audio and video (primarily TV-sets, tablets and smartphones) based on the Digital Living Network Alliance (DLNA) in order to share multimedia contents between those devices.
The company’s software development kits allows modernizing a stereo system for music listening from a computer, transforming a TV-set into a tool for watching videos from smartphone or the Web, and also converting a standard bulb into a loud speaker connected to a tablet.

EnterNext welcomes Genfit on Euronext's market in Paris

Jean-François Mouney, CEO of GENFIT, opens the European trading day in Paris.

Genfit is a leading European biopharmaceutical group. It specializes in the discovery and development of drugs for preventing and treating risk factors related to cardiometabolic pathologies (atherosclerosis, dyslipidemias, hypertension, diabetes, obesity, etc.) and inflammatory diseases. Genfit's development model, which allies internally financed research programs with partner-supported programs, allows it to manage the associated risks while generating value for its shareholders. Working both on its own behalf and for large industrial pharmaceutical group accounts, Genfit has developed a rich and diversified portfolio of promising drugs in the clinical and pre-clinical development phases.

EnterNext welcomes Genfit on Euronext's market in Paris

Jean-François Mouney, CEO of GENFIT, opens the European trading day in Paris.

Genfit is a leading European biopharmaceutical group. It specializes in the discovery and development of drugs for preventing and treating risk factors related to cardiometabolic pathologies (atherosclerosis, dyslipidemias, hypertension, diabetes, obesity, etc.) and inflammatory diseases. Genfit's development model, which allies internally financed research programs with partner-supported programs, allows it to manage the associated risks while generating value for its shareholders. Working both on its own behalf and for large industrial pharmaceutical group accounts, Genfit has developed a rich and diversified portfolio of promising drugs in the clinical and pre-clinical development phases.